REBEC

Public trial

Usefulness of Complete Blood Count and Ferritin Measurement in the Anemia Diagnosis in Pregnancy

Date of registration: 01/03/2013 ^(mm/dd/yyyy)
Last approval date : 01/03/2013 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Study of IMC-1121B (ramucirumab) with Best Supportive Care in patients with gastric cancer and adenocarcinoma

Date of registration: 01/02/2013 ^(mm/dd/yyyy)
Last approval date : 01/02/2013 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of citrate content dialysate in patients on hemodialysis

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Reduction in blood pressure after cycle ergometer exercise and its physiological regulators: influence of time and association with hormone variation.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Study for comparative evaluation of efficacy and safety of nitrendipino (Caltren) versus nifedipino (Adalat retard) in the treatment of mild arteial hypertension.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of mirror therapy associated with functional tasks in arm function after stroke

Date of registration: 07/07/2011 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Effects of two physiotherapy approaches in patients with low back pain

Date of registration: 11/06/2011 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Analysis of the effect of vibration in patients with stroke

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Physical Exercises, neuropsychiatric disturbances and Activity Daily Living performance on women with Alzheimer´s Disease.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison among two drugs commonly used in the prevention and treatment of thrombosis, to prevent thromboembolism after total cavopulmonary operation.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of a Pilates exercise program on flexibility, muscle performance and balance of elderly women.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison of the effectiveness of the use of pads in adult patients admitted to the Intensive Care Unit

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of manipulation of foot muscles in people who have acquired brain injury

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Treating lymphangioleiomyomatosis with doxycycline

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The melatonin analgesic effect in a human pain model

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Oral splint and counselling for the treatment of chronic facial pain

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Cardiac responses during rehabilitation in patients undergoing cardiac surgery

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of exercise in ovseweight nondialyis dependent chronic kidney disease patients.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison of methods of oral rehydration therapy in children with acute diarrhea.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of a type of therapy for the treatment of vaginal pain during intercourse.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

08/28/2026

Clinical trial tests new way to treat common inherited heart disease

08/28/2026 | Erik Robinson | OHSU News

https://news.ohsu.edu/2026/08/28/clinical-trial-tests-new-way-to-treat-common-inherited-heart-disease

OHSU investigator leads international clinical trial studying potential treatment for nonobstructive hypertrophic cardiomyopathy

People living with a serious heart condition that has few treatments appear to benefit from an interventional drug, according to results of a randomized clinical trial reported today in the New England Journal of Medicine.

The lead investigator from Oregon Health & Science University also reported the results during the European Society of Cardiology Congress 2026 in Munich.

The drug, known as aficamten, was developed by Cytokinetics, a San Francisco Bay Area-based biopharma company, and initially targeted an obstructive form of hypertrophic cardiomyopathy, which is a thickening of the heart muscle that’s usually inherited. Today, researchers reported results from a Phase 3 placebo-controlled randomized clinical trial testing the treatment on people with a nonobstructive form of the condition.

For that group of patients, the condition isn’t necessarily deadly with modern management, but it can be debilitating by greatly reducing their ability to exercise or even to walk.

“Based on this trial, this is the first-ever successful therapy for nonobstructive hypertrophic cardiomyopathy,” said lead author Ahmad Masri, M.D., M.S., associate professor of medicine (cardiovascular medicine) in the OHSU School of Medicine. “These results are highly encouraging for patients with this condition and for cardiologists who struggle to help them.”

Hypertrophic cardiomyopathy affects an estimated 1 in 350 people worldwide, with about half living with the non-obstructive…

08/28/2026

How AI Could Accelerate Clinical Trial Design and Patient Recruitment

08/28/2026 | Emily Schoenthaler, Eron Kelly, Shaalan Beg | Biopharm International

https://www.biopharminternational.com/view/how-ai-could-accelerate-clinical-trial-design-and-patient-recruitment

Eron Kelly, CEO of ConcertAI, and Shaalan Beg, MD, chief medical officer, oncology, ConcertAI, discuss how artificial intelligence (AI) can accelerate clinical trial design, patient identification, and site selection while maintaining trust in clinical data.

Artificial intelligence (AI) could significantly reduce the time required for several traditionally labor-intensive steps in clinical trial planning, according to Eron Kelly, CEO of ConcertAI, and Shaalan Beg, MD, chief medical officer, oncology, ConcertAI, who discussed the technology’s potential in a recent video interview with BioPharm International.

Kelly explained that AI reasoning models can rapidly digitize inclusion and exclusion criteria, compare a proposed trial with similar studies listed on ClinicalTrials.gov, and identify relevant trial attributes. Tasks that previously required weeks of manual review could potentially be completed in minutes, he said.

How can AI improve clinical trial design and patient recruitment?
AI can also help sponsors assess whether an appropriate patient population exists within the current standard of care, particularly for second-line therapies. Kelly said these analyses can help sponsors identify potential clinical trial sites based on historical patient populations and ultimately accelerate enrollment and drug development.

The potential benefits extend to patients as well as sponsors, Kelly said, because faster trial execution could help patients access investigational treatments while enabling sponsors to bring therapies to market more…

08/28/2026

A new sarcoma clinical trial bridges adolescent and adult care at the MUHC

08/28/2026 | McGill University Health Centre

https://muhc.ca/news-and-patient-stories/news/new-sarcoma-clinical-trial-bridges-adolescent-and-adult-care-muhc

Highlighting the MUHC’s unique ability to bridge pediatric and adult cancer care, the trial evaluates a new antibody-drug conjugate for the treatment of osteosarcoma and soft tissue sarcomas in adolescents and adults.

Adolescents and adults with difficult-to-treat sarcomas can now access a new investigational treatment at the McGill University Health Centre (MUHC), through the Phase Ib/II EMBOLD Sarcoma clinical trial. The study brings together the MUHC’s pediatric and adult oncology teams to offer the same trial to patients aged 12 and older, an approach made possible by the MUHC’s unique continuum of cancer care. The trial is locally coordinated by the Research Institute of the MUHC (The Institute).

Sarcoma is a rare cancer that primarily affects adolescents and young adults. Approximately 2,000 new cases are diagnosed each year in Canada and despite advances made in recent decades, treatment options remain limited.

“Clinical trials in sarcoma are particularly valuable. These cancers account for only about one per cent of cancers in adults and encompass many subtypes that affect both adolescents and adults, making participant recruitment and the generation of robust evidence particularly challenging. In this context, every participant counts, and the opening of a new trial marks an important milestone in the search for better treatments,” says Dr. Ramy Saleh, medical oncologist at the MUHC’s Cedars Cancer Centre, Medical Director of Oncology Clinical Trials and the Phase I Research Unit at The Institute, and Associate Professor in the Gerald Bronfman Department of Oncology at McGill…

08/28/2026

How personalised behavioural interventions could transform healthy ageing

08/28/2026 | Innovation NewsNetwork

https://www.innovationnewsnetwork.com/how-personalised-behavioural-interventions-could-transform-healthy-ageing/73368/

The Northwell Roybal Center for Personalized Trials uses state-of-the-art behavioural theory and personalised approaches to improve the health of older adults
Modifiable health behaviours account for nearly half of deaths in the United States, with the burden of modifiable chronic disease being especially significant among those aged 60 years or older. Despite the importance of modifying health behaviours to improve health and reduce mortality in older adults, large-scale, stable health behaviour change has been difficult to achieve. Well-designed behavioural interventions are critical to supporting consistent health behaviour change.

The Edward R. Roybal Centers
The goal of the National Institute of Health’s (NIH) National Institute on Aging (NIA) is to support innovative research that fosters the health and independence of older adults while studying the conditions that uniquely affect the most vulnerable among America’s ageing population. The Edward R. Roybal Centers for Translational Research in the Behavioural and Social Sciences of Aging are a NIA-supported consortium of 15 Centers created to help achieve this goal. The Roybal Centers conduct research to translate and integrate basic behavioural and social research findings into interventions that improve the lives of older people and increase institutional capacity to adapt to societal ageing.

Northwell Health is proud to be a member of the Roybal Consortium and to support the work of the consortium as the Roybal Coordinating Center, providing strategic leadership and coordination to the Edward R. Roybal Centers for Translational…

08/28/2026

As the dream of the autonomous clinical trial dawns, agent supervision is today’s human job

08/27/2026 | Brian Buntz | Drug Discovery&Development

https://www.drugdiscoverytrends.com/as-the-dream-of-the-autonomous-clinical-trial-dawns-agent-supervision-is-todays-human-job/

In 2020, the average phase 3 protocol collected approximately 3.56 million data points. By 2025, that figure had reached about 5.96 million, a five-year increase of 67% and 6.4 times the 2012 average of 929,203, according to collaborative research from the nonprofit industry group TransCelerate BioPharma and the Tufts Center for the Study of Drug Development. The study found potential room for greater discipline as nearly one-third of phase 3 procedures and associated data were classified as non-core or non-essential. The peer-reviewed paper also noted that AI and ML processing power “may be serving as a disincentive to reduce data volume.”

Nearly eight months later, that observation about AI looks prescient. “I don’t think [sponsors] are as worried about collecting too much data,” said Venu Mallarapu, chief transformation and AI officer at eClinical Solutions. He argued that AI has made expanding datasets easier to manage and analyze, while sensors and wearables could drive volumes higher still. “Of course, you still want to make sure that you’re collecting the right data,” Mallarapu said. “But crunching that data and generating the insights that would be required, AI has certainly made that a lot easier with the powerful capability of some of the models.”

Where agents are landing first
The data processing layer is one layer; the other lies in the complexity of collecting the data, whether it is staff, say, collecting a patient’s blood, running the imaging or sitting with the patient through the questionnaire.…